Company intelligence / Profile preview

AdaptVac

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

AdaptVac’s lead candidate ABNCoV2, a COVID‑19 vaccine based on its cVLP platform, has demonstrated non-inferiority to the Comirnaty® mRNA vaccine in Phase III trials. The vaccine showed a strong safety profile with no serious adverse events among over four thousand participants. The company’s cVLP technology has also shown best-in-class durable antibody responses at twelve months in Phase II studies. The validated platform underpins additional programs targeting oncology and emerging infectious diseases such as Nipah virus.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Virus-like particles (VLPs)Capsid Virus-like Particles (cVLPs)
Industry: Biotech

Drug pipeline

10 assets

PAMVAC

9 more assets in the full pipeline.

Request access →

Partnerships

ExpreS^ion Biotechnologies ApSUniversity of CopenhagenNextGen Vaccines ApScollaborations with academic institutions for R&D and clinical development

Beyond the preview

Go deeper on AdaptVac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdaptVac.

Explore the full profile